KHB(SZ:002022)2022-12-06 08:26Group 1: Company Overview and Leadership - The new president of the company is Ding Wei, introduced during the investor relations activity [2] - The company is focused on maintaining a market-driven incentive model for its team [3] Group 2: Business Operations and Market Strategy - The approval process for the company's export business is lagging behind expectations, with efforts to expedite the WHO internal review process [2] - The chemical luminescence business is in the market introduction phase, with 33 products registered and expected to see significant revenue growth next year [3] - The company has distinct market positioning for its acquisitions: TGS for mid-to-high-end markets and Biokit for lightweight instruments catering to various market needs [3][4] Group 3: Financial Performance and Future Projections - The company anticipates stable and rapid sales growth from blood screening tenders due to national policies, with a focus on systematic data collection from existing contracts [4] - The company is pursuing a strategy of "internal growth + external mergers," emphasizing technology and product advantages in future acquisitions [4] Group 4: Product Development and Market Adaptation - The company’s biochemical instruments are primarily closed systems, but can be adapted to meet market demands for either open or closed systems [4]